Friday, July 31, 2015
FDA OK’s BMS Daklinza (Daclatasvir) to Treat Hep C Genotype 3
The U.S. Food and Drug Administration (FDA) has approved Bristol-Myers Squibb’s (BMS) NS5A inhibitor Daklinza (daclatasvir) to be used in combination with Gilead Sciences’ Sovaldi (sofosbuvir) to treat genotype 3 of hepatitis C. This is the first hep C regimen ever to be specifically approved for genotype 3, and it improves cure rates over other currently available treatments. However, the cure rate anticipated for those with cirrhosis is still quite poor.
Twelve weeks of once-daily regimen is recommended.
An estimated 12 percent of Americans with hep C are infected with genotype 3. It is the second most common genotype in the United States, behind genotype 1, which makes up about 70 percent of the U.S. epidemic. Read more....
Twelve weeks of once-daily regimen is recommended.
An estimated 12 percent of Americans with hep C are infected with genotype 3. It is the second most common genotype in the United States, behind genotype 1, which makes up about 70 percent of the U.S. epidemic. Read more....
Hepatitis C warning from the state
A week ago we told you that Hepatitis C was almost at epidemic status. Now the state health department says beware it
A week ago, we told you that Hepatitis C was almost at epidemic status. Now the state health department says beware it's there. More than 100,000 people in Tennessee are living with it and don't even know they're infected, it could be you.
We talked to a girl who has it. She was a good girl who got in with the wrong crowd. Now she's got a life threatening illness that could steal her away from her children. By the way, we'll call her Amy since she wants to keep her identity hidden. Read more....
A week ago, we told you that Hepatitis C was almost at epidemic status. Now the state health department says beware it's there. More than 100,000 people in Tennessee are living with it and don't even know they're infected, it could be you.
We talked to a girl who has it. She was a good girl who got in with the wrong crowd. Now she's got a life threatening illness that could steal her away from her children. By the way, we'll call her Amy since she wants to keep her identity hidden. Read more....
Gilead Sales Soar on Hepatitis Drugs - Sales of Harvoni, Sovaldi top estimates despite increased competition
Gilead Sciences Inc. said its two key hepatitis C drugs, Sovaldi and Harvoni, generated about $4.9 billion in sales in the second quarter, topping Wall Street estimates, thanks to better-than-expected sales of the newer Harvoni.
For the year, the company again raised its guidance for net product sales, this time by $1 billion, and now expects sales to reach $29 billion to $30 billion.
Shares of Gilead, up 24% over the past year, rose 3.2% to $116.99 in recent after-hours trading.
Read more...http://www.wsj.com/articles/gilead-sales-soar-on-hepatitis-drugs-1438114949
For the year, the company again raised its guidance for net product sales, this time by $1 billion, and now expects sales to reach $29 billion to $30 billion.
Shares of Gilead, up 24% over the past year, rose 3.2% to $116.99 in recent after-hours trading.
Read more...http://www.wsj.com/articles/gilead-sales-soar-on-hepatitis-drugs-1438114949
Thursday, July 23, 2015
The Top 5 Best Analyst Coverage on Gilead Sciences, Inc (GILD) Ahead of Earnings
Gilead Sciences, Inc. (NASDAQ:GILD) will release second quarter earnings on Tuesday, July 28. The biopharmaceutical giant is most known for its hepatitis C drugs, Harvoni and Sovaldi. Several analysts weighed in on Gilead after the company posted a strong earnings report in May. Here are the top 5 analysts to follow ahead of the upcoming earnings release:
1. Alan Carr of Needham most recently weighed in on Gilead on May 1, reiterating a Buy rating on the stock with an unchanged priced target of $120. Carr made the rating in light of the company’s first quarter earnings report in which the company posted better-than-expected results. The analyst attributed the strong earnings to Harvoni and to an adjustment made in Branded Prescription Fee. At the time, the analyst correctly predicted that Harvoni would be approved in Japan later in the year. He also commented, “Top-line results from Phase 3 ASTRAL program testing 12-wk sof/ GS-5816 [a pipeline drug aimed at chronic HCV infection] are expected in 3Q15, followed by NDA submission in 4Q15.” The pipeline drug is still in Phase 3 testing.
Alan Carr has rated Gilead 15 times since February 2012, earning a 100% success rate recommending the stock and a +55.4% average return per GILD rating when measured over a one-year horizon and no benchmark.
READ MORE...
http://www.smarteranalyst.com/2015/07/23/top-5-analysts-to-watch-ahead-of-gilead-sciences-incs-gild-earnings/
1. Alan Carr of Needham most recently weighed in on Gilead on May 1, reiterating a Buy rating on the stock with an unchanged priced target of $120. Carr made the rating in light of the company’s first quarter earnings report in which the company posted better-than-expected results. The analyst attributed the strong earnings to Harvoni and to an adjustment made in Branded Prescription Fee. At the time, the analyst correctly predicted that Harvoni would be approved in Japan later in the year. He also commented, “Top-line results from Phase 3 ASTRAL program testing 12-wk sof/ GS-5816 [a pipeline drug aimed at chronic HCV infection] are expected in 3Q15, followed by NDA submission in 4Q15.” The pipeline drug is still in Phase 3 testing.
Alan Carr has rated Gilead 15 times since February 2012, earning a 100% success rate recommending the stock and a +55.4% average return per GILD rating when measured over a one-year horizon and no benchmark.
READ MORE...
http://www.smarteranalyst.com/2015/07/23/top-5-analysts-to-watch-ahead-of-gilead-sciences-incs-gild-earnings/
New Drug Combination Treats Hepatitis C Patients Also Infected With HIV
Roughly 20 percent to 30 percent of patients with hepatitis C virus (HCV) are also infected with human immunodeficiency virus type 1 (HIV). Both bloodborne viruses share the same modes of transmission, but many HCV medications currently have significant limitations due to adverse interactions with HIV treatments. Researchers at University of California, San Diego School of Medicine report a new combination that effectively treats HCV in patients co-infected with HIV.
The study, published online in the New England Journal of Medicine, found the combination of HCV drugs daclatasvir and sofosbuvir -- both pills -- cured HCV in 97 percent of patients also infected with HIV.
"In many HCV/HIV co-infected patients, HCV therapies can have a strong interaction with HIV medications that complicate or potentially exclude them from HCV treatment," says David Wyles, MD, lead author of the study in the Division of Infectious Diseases. "This study is novel because it shows the new drug combination was not compromised when used with a wide range of HIV medications, increasing the number of HCV/HIV patients who can be treated without modifying their HIV medications."
READ MORE...http://www.infectioncontroltoday.com/news/2015/07/new-drug-combination-treats-hepatitis-c-patients-also-infected-with-hiv.aspx
The study, published online in the New England Journal of Medicine, found the combination of HCV drugs daclatasvir and sofosbuvir -- both pills -- cured HCV in 97 percent of patients also infected with HIV.
"In many HCV/HIV co-infected patients, HCV therapies can have a strong interaction with HIV medications that complicate or potentially exclude them from HCV treatment," says David Wyles, MD, lead author of the study in the Division of Infectious Diseases. "This study is novel because it shows the new drug combination was not compromised when used with a wide range of HIV medications, increasing the number of HCV/HIV patients who can be treated without modifying their HIV medications."
READ MORE...http://www.infectioncontroltoday.com/news/2015/07/new-drug-combination-treats-hepatitis-c-patients-also-infected-with-hiv.aspx
Subscribe to:
Posts (Atom)